ENDACEA Saves Lives
Healthcare, at its core, is about saving lives. This is the aim of ENDACEA (RTP, NC) – to connect scientific expertise with medical technologies to design life-changing solutions. Since 1996, it has been at the forefront of biopharmaceutical research and development and continues to move forward.
Led by Constance Neely Wilson, M.D, the company is outsourcing operations and taking an advanced approach in delivering significant innovations. This includes a mutant plasmid cDNA for the A1 adenosine receptor as a treatment for cancer, and its lead compound A1 adenosine receptor antagonist, L-97-1, as an inhalational treatment for COVID-19 acute lung injury and as an intravenous treatment for sepsis and acute renal failure.
Copyright © 2001-2012 Endacea, Inc. ENDACEA and the ENDACEA logo are trademarks of Endacea, Inc.